It's the right time to be decisive, if you can tolerate uncertainty.
News & Analysis: Surface Oncology, Inc
Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.
The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.
Its pancreatic cancer drug gets a nod from the FDA.
Investors reacted negatively to a big licensing deal.
The small biotech could be preparing to sell to a big drugmaker.